Abemaciclib/Anastrozole Combo Shows Promise in HR+/HER2- Breast Cancer
December 10th 2016A neoadjuvant regimen combining the CDK4/6 inhibitor abemaciclib with anastrozole induced a response rate of 54.7% in patients with HR+/HER2-negative early-stage breast cancer, according to findings from the phase II neoMONARCH trial presented at the 2016 San Antonio Breast Cancer Symposium.
Read More
METRIC Trial Has Potential to Reform TNBC Landscape
December 9th 2016Denise A. Yardley, MD, shares the rationale for the METRIC trial, the uniqueness of glembatumumab vedotin, and how the antibody-drug conjugate has the power to transform the field of triple-negative breast cancer.
Read More
Ongoing Trial of Abemaciclib and Pembrolizumab in HR+/HER2-Negative Breast Cancer
December 9th 2016Maura N. Dickler, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses an ongoing clinical trial of the CDK4/6 inhibitor abemaciclib combined with the PD-L1 inhibitor pembrolizumab (Keytruda) for patients with hormone receptor (HR)-positive, HER2-negative breast cancer. She also sheds light on abemaciclib's unique mechanism of action.
Watch
Buparlisib Combo Shows Modest PFS Improvement in Pretreated HR+ Breast Cancer
December 9th 2016Median progression-free survival was improved by 2.1 months with the addition of the pan-PI3K inhibitor buparlisib to fulvestrant for women with HR-positive/HER2-negative advanced breast cancer who received a prior aromatase inhibitor and progressed on or after an mTOR inhibitor.
Read More
Phase III Study Does Not Support Use of Extended Anastrozole After Adjuvant Tamoxifen
December 9th 2016Using extended adjuvant aromatase inhibitor (AI) therapy after 5 years of sequential endocrine therapy in all postmenopausal women with hormone receptor-positive early breast cancer is not supported by the results of a phase III randomized study.
Read More
Resistance Mutations in ER+ Breast Cancer Uncovered in Genomic Study
December 9th 2016In a study that sheds light on acquired resistance mechanisms to anticancer therapies, the genomic landscape of recurrent metastatic estrogen receptor (ER)–positive breast cancer differed significantly from the mutational profile of primary disease.
Read More
Adjuvant Ibandronate Added No Additional Benefit in Postmenopausal Breast Cancer
December 9th 2016Adjuvant ibandronate (Boniva) added to hormone therapy did not provide a clinical benefit to postmenopausal patients with HR-positive, early-stage breast cancer, according to findings from the phase III TEAM IIB trial.
Read More
Potential for Glembatumumab Vedotin in TNBC
December 9th 2016Linda T. Vahdat, MD, PhD, Breast Cancer Research Program Leader at Meyer Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian, discusses the ongoing METRIC trial and the potential for glembatumumab vedotin as a treatment for patients with triple-negative breast cancer (TNBC).
Watch
HER2-Enriched Subtype Strong Predictor of Response to Dual HER2 Blockade
December 9th 2016The <em>HER2</em>-enriched subtype of HER2-positive breast cancer is a strong predictor of sensitivity to dual HER2 blockade without the use of chemotherapy, according to findings presented at the 2016 San Antonio Breast Cancer Symposium.
Read More
Hormonal Therapy Improved PFS When Added to Dual HER2-Targeted Therapy
December 9th 2016The addition of an aromatase inhibitor (AI) to pertuzumab (Perjeta) and trastuzumab (Herceptin) improved progression-free survival (PFS) by 3.09 months, when compared with trastuzumab plus an AI, according to findings from the phase II PERTAIN trial.
Read More
Osimertinib Greatly Reduces Disease Progression Risk in EGFR T790M-Mutant NSCLC
December 8th 2016Osimertinib (Tagrisso) reduced the risk of disease progression by 70% compared with a chemotherapy doublet in patients with EGFR T790M-mutant non–small cell lung cancer (NSCLC) who progressed after first-line targeted therapy, according to phase III clinical trial results.
Read More
Results Mixed for Veliparib Regimen in BRCA+ Breast Cancer
December 8th 2016The addition of the veliparib to carboplatin/paclitaxel demonstrated promising objective response rates and trends toward improvements in progression-free survival and overall survival in patients with advanced <em>BRCA</em>-positive breast cancer.
Read More
Longer Letrozole Treatment Shows Limited Benefit in Early Breast Cancer
December 8th 2016Extending treatment with letrozole by an additional 5 years after 5 years of successful treatment did not improve disease-free survival or overall survival in postmenopausal women with early-stage hormone receptor -positive breast cancer.
Read More
Everolimus/Fulvestrant Combo Improves PFS in HR+ Breast Cancer
December 8th 2016Adding everolimus to fulvestrant reduced the risk of progression or death by 40% compared with fulvestrant alone for postmenopausal patients with metastatic HR-positive, HER2-negative breast cancer who are resistant to aromatase inhibitor therapy.
Read More
Margetuximab Plus Chemotherapy in HER2+ Breast Cancer
December 8th 2016Mark D. Pegram, MD, director of the Breast Cancer Oncology Program, Stanford Women’s Cancer Center, co-director of Molecular Therapeutics Program, Stanford Medicine, discusses the phase III SOPHIA trial, which is exploring margetuximab plus chemotherapy versus trastuzumab plus chemotherapy in the treatment of patients with HER2-positive breast cancer.
Watch
KEYNOTE-010 Shows Overall Survival Benefit of Pembrolizumab in NSCLC
December 8th 2016Roy. S. Herbst, MD, PhD, professor of Medicine (Medical Oncology), professor of Pharmacology, chief of Medical Oncology, Yale Cancer Center, discusses the phase III KEYNOTE-010 study, in which pembrolizumab provided superior overall survival over docetaxel in patients with previously treated, PD-L1-expressing advanced non-small cell lung cancer. He discussed these results during an interview at the IASLC 17th World Conference on Lung Cancer.
Watch
Ropeginterferon as Effective but Safer Than Hydroxyurea in Polycythemia Vera
December 7th 2016Ropeginterferon alfa-2b is noninferior to hydroxyurea in terms of complete hematologic response for the treatment of polycythemia vera, and has the advantage of being a safer and more tolerable therapy.
Read More
A Study of Brentuximab Vedotin and Nivolumab in Relapsed or Treatment-Resistant Hodgkin Lymphoma
December 7th 2016Alex Herrera, MD, assistant professor, City of Hope, discusses a study investigating the use of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) in the treatment of relapsed or treatment-resistant Hodgkin lymphoma during the American Society of Hematology (ASH) Annual Meeting.
Watch
High Response Rate With Venetoclax in Relapsed/Refractory CLL
December 7th 2016Two-thirds of patients with chronic lymphocytic leukemia that progressed on B-cell receptor pathway inhibitors had objective responses to treatment with venetoclax (Venclexta), results of a small open-label trial showed.
Read More
KTE-C19 Treatment Shows Impressive Responses in Aggressive Lymphomas
December 6th 2016Treatment with the CD19-directed CAR T-cell therapy KTE-C19 showed a complete remission rate of 73% for patients with aggressive, chemorefractory primary mediastinal B-cell lymphoma and transformed follicular lymphoma, according to findings from the multicenter phase II ZUMA-1 study.
Read More
A Study Examining Brentuximab Vedotin in Patients With High-Risk Large B-Cell Lymphoma
December 6th 2016Kathryn Kolibaba, MD, associate chair of hematology research program, US Oncology, discusses an ongoing phase 2 study of brentuximab vedotin (Adcetris) with as frontline therapy in patients with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL).<br />
Watch
An Overview of a Study Combining Nivolumab With Ibrutinib in CLL and Richter Transformation
December 6th 2016Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses a phase II trial combining nivolumab (Opdivo) with ibrutinib (Imbruvica) for chronic lymphocytic leukemia (CLL) and richter transformation (RT) during the American Society of Hematology (ASH) Annual Meeting.<br />
Watch
Enasidenib Treatment Active in Pretreated Patients With IDH2-Mutant MDS
December 6th 2016Treatment with enasidenib (AG221) was active and was well tolerated in pretreated patients with IDH2-mutated myelodysplastic syndrome, including those who failed hypomethylating agents, according to findings from a phase I/II study.
Read More
Induction of Ibrutinib Regimen Achieves 100% Response Rate in CLL
December 6th 2016Combination induction therapy with ibrutinib (Imbruvica) and obinutuzumab (Gazyva) after bendamustine debulking induced a 100% response rate in patients with chronic lymphocytic leukemia (CLL), according to findings from the phase II CLL2-BIG trial.
Read More
Early Signs of Activity From Lirilumab/Azacytidine Combo in Heavily Pretreated AML
December 6th 2016The combination of lirilumab and azacytidine was well tolerated and showed early signals of activity in heavily pretreated patients with acute myeloid leukemia (AML), according to phase Ib/II findings presented at the 2016 ASH Annual Meeting.
Read More
Lenalidomide Maintenance Substantially Improved PFS in High-Risk Subgroup of CLL
December 5th 2016Lenalidomide as maintenance following first-line immunochemotherapy substantially improves progression-free survival in the treatment of patients with high-risk chronic lymphocytic leukemia (CLL), according to interim analysis of the phase III CLLM1 study.
Read More